The antimicrobial susceptibility pattern of extended-spectrum beta-lactamase producing Escherichia coli in Surabaya, Indonesia
Abstract number: 1134_01_40
Kuntaman K., Mertaniasih N.M., Purwanta M., Hadi U., Verbrugh H.A.
To study the susceptibility pattern of ESBL (Extended spectrum beta lactamase) producing Escherichia coli from clinical isolates against commonly used antimicrobial agents.
The study was conducted in Dr. Soetomo Hospital with 1500 beds capacity in Surabaya, Indonesia. All clinical isolates Escherichia coli resistant to third generation cephalosporine in the routine examination were included in this study. The susceptibility test was performed by disk diffusion test (NCCLS, 2002). The phenotypic confirmatory test for ESBL was performed by disk diffusion test using ceftazidime disk (CAZ) and combination ceftazidime plus clavulanic acid (CD). A 5 millimeter in zone around CD compare to CAZ, was used to identify ESBL producer. These isolates were further tested against Ceftazidime (CAZ), Cefotaxim (CTX), Ceftriaxone (CRO), Ciprofloxacin (CIP), Cefixim (CFM), Cefepim (FEP), Meropenem (MEM) and Cefoperazone-sulbactam (SCF).
During January to September 2004, 435 clinical strains of E. coli, including 358 strains (82.3%) from urine specimens were included. 57 strains (10.8%) were confirmed as ESBL producers. The antimicrobial susceptibility pattern (in % of S = Susceptible, I = Intermediate, R = Resistance) against the tested antimicrobials were as follow: S, I, R (%) against CAZ 19.3, 28.1, 52.6; CTX 0, 7, 93; CRO 8.8, 17.5, 73.7; CIP 19.3, 3.5, 77.2; CFM 5.3, 5.3, 89.5; FEP 43.9, 26.3, 29.8; MEM 94.7, 0, 5.3; SCF 78.9, 17.5, 3.5.
ESBL producing Escherichia coli were frequently isolated in this region of the world, they mostly resistant to ceftazidime (52.6%), cefotaxime (93%), ceftriaxone (73.7%) and ciprofloxacine (77.2%), and on the lesser extend to cefepime (29.8%). The resistance rate to the second tier agents meropenem and the combination of cefoperazone-sulbactam, was very low, 5.5% and 3.3% respectively.
|Session name:||XXIst ISTH Congress|
|Back to top|